Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Adagrasib

FDA-approved product (tablet, oral), marketed as Krazati.

Registered studies
40
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Adagrasib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

40registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Adagrasib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Adagrasib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

    NCT07543172 · start 2026-10-15

    Registered record
    Registry ID
    NCT07543172
    Conditions
    Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
    Interventions
    Adagrasib; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-15
    Completion
    2029-06-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
    InterventionAdagrasib; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

    NCT07723118 · start 2026-08-05

    Registered record
    Registry ID
    NCT07723118
    Conditions
    Healthy Participants
    Interventions
    Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-08-05
    Completion
    2026-09-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAdagrasib
    PhasePhase 1
    Registry statusRecruiting

  • ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

    NCT07318389 · start 2026-06-10

    Registered record
    Registry ID
    NCT07318389
    Conditions
    Dynamic Tumor Resistance; Metastatic Colorectal Cancer
    Interventions
    SOC (Standard of care); Bevacizumab; Cetuximab; Panitumumab; FOLFIRI; FOLFOX; Encorafenib; Adagrasib; Trifluridine/tipiracil (TAS-102); Trastuzumab deruxtecan; Tucatinib; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-06-10
    Completion
    2029-11-14
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDynamic Tumor Resistance; Metastatic Colorectal Cancer
    InterventionSOC (Standard of care); Bevacizumab; Cetuximab; Panitumumab +8 more
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

    NCT07382726 · start 2026-05-15

    Registered record
    Registry ID
    NCT07382726
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Adagrasib; Iza-bren
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-05-15
    Completion
    2029-12-24
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionAdagrasib; Iza-bren
    PhasePhase 1
    Registry statusRecruiting

  • A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

    NCT07415031 · start 2026-05-06

    Registered record
    Registry ID
    NCT07415031
    Conditions
    Solid Tumors
    Interventions
    Adagrasib; Pembrolizumab; Cetuximab; Pemetrexed; Docetaxel; Irinotecan; Leucovorin; Oxaliplatin; Fluorouracil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-06
    Completion
    2028-02-16
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionAdagrasib; Pembrolizumab; Cetuximab; Pemetrexed +5 more
    PhasePhase 2
    Registry statusRecruiting

  • Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

    NCT07288034 · start 2026-04-08

    Registered record
    Registry ID
    NCT07288034
    Conditions
    Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
    Interventions
    Adagrasib; Anti-PD-L1 Monoclonal Antibody; Anti-PD1 Monoclonal Antibody; Bevacizumab; Biopsy Procedure; Biospecimen Collection; Chemotherapy; Computed Tomography; Durvalumab; Magnetic Resonance Imaging; Monitoring; Positron Emission Tomography; Surveillance; Tremelimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-04-08
    Completion
    2028-10-08
    Enrolment
    535

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
    InterventionAdagrasib; Anti-PD-L1 Monoclonal Antibody; Anti-PD1 Monoclonal Antibody; Bevacizumab +10 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    NCT06875310 · start 2025-04-24

    Registered record
    Registry ID
    NCT06875310
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Adagrasib; Pembrolizumab; Carboplatin; Pemetrexed; Placebo; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-24
    Completion
    2032-04-30
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionAdagrasib; Pembrolizumab; Carboplatin; Pemetrexed +2 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

    NCT06764771 · start 2025-03-25

    Registered record
    Registry ID
    NCT06764771
    Conditions
    Advanced Malignant Tumors
    Interventions
    BMS-986488; Adagrasib; Cetuximab; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-03-25
    Completion
    2027-10-15
    Enrolment
    437

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Tumors
    InterventionBMS-986488; Adagrasib; Cetuximab; Nivolumab
    PhasePhase 1
    Registry statusRecruiting

  • Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets

    NCT06801418 · start 2025-02-04

    Registered record
    Registry ID
    NCT06801418
    Conditions
    Healthy Volunteers
    Interventions
    Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-02-04
    Completion
    2025-06-19
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAdagrasib
    PhasePhase 1
    Registry statusCompleted

  • Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

    NCT06481813 · start 2024-12-10

    Registered record
    Registry ID
    NCT06481813
    Conditions
    Lung Cancer; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma; Metastatic Lung Cancer
    Interventions
    Blood Sampling (2*8mL Tubes); PBMC Sampling (1*8mL Tubes); Paxgene Sampling; Extended biopsies of tumor lesions
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-12-10
    Completion
    2034-12-01
    Enrolment
    730

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma; Metastatic Lung Cancer
    InterventionBlood Sampling (2*8mL Tubes); PBMC Sampling (1*8mL Tubes); Paxgene Sampling; Extended biopsies of tumor lesions
    PhaseNot applicable
    Registry statusRecruiting

  • A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

    NCT06497556 · start 2024-09-23

    Registered record
    Registry ID
    NCT06497556
    Conditions
    Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
    Interventions
    Divarasib; Sotorasib; Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-09-23
    Completion
    2029-11-30
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; KRAS G12C Lung Cancer
    InterventionDivarasib; Sotorasib; Adagrasib
    PhasePhase 3
    Registry statusActive not recruiting

  • A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

    NCT06412198 · start 2024-08-28

    Registered record
    Registry ID
    NCT06412198
    Conditions
    Metastatic Colorectal Cancer; KRAS G12C Mutations
    Interventions
    Cetuximab; Cemiplimab; Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-08-28
    Completion
    2029-03-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer; KRAS G12C Mutations
    InterventionCetuximab; Cemiplimab; Adagrasib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

    NCT06248606 · start 2024-08-06

    Registered record
    Registry ID
    NCT06248606
    Conditions
    Non Small Cell Lung Cancer; NSCLC; KRAS G12C
    Interventions
    Adagrasib; Stereotactic Radiosurgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-08-06
    Completion
    2028-02-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; NSCLC; KRAS G12C
    InterventionAdagrasib; Stereotactic Radiosurgery
    PhasePhase 2
    Registry statusRecruiting

  • Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

    NCT05853575 · start 2024-02-01

    Registered record
    Registry ID
    NCT05853575
    Conditions
    Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung
    Interventions
    Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-02-01
    Completion
    2026-11-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung
    InterventionAdagrasib
    PhasePhase 2
    Registry statusActive not recruiting

  • Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

    NCT06130254 · start 2024-01-30

    Registered record
    Registry ID
    NCT06130254
    Conditions
    Advanced Solid Tumor; Non-small Cell Lung Cancers
    Interventions
    Adagrasib; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2024-01-30
    Completion
    2026-03-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; Non-small Cell Lung Cancers
    InterventionAdagrasib; Olaparib
    PhasePhase 1
    Registry statusTerminated